{"id":"bcd-132","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"}]},"_chembl":{"chemblId":"CHEMBL320633","moleculeType":"Small molecule","molecularWeight":"484.51"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BCD-132 is a fully human monoclonal antibody designed to target programmed death ligand 1 (PD-L1) on tumor cells and immune cells. By blocking PD-L1, the drug prevents the suppression of T-cell mediated anti-tumor immunity, allowing the immune system to recognize and attack cancer cells more effectively. This mechanism is similar to other checkpoint inhibitors in the immuno-oncology space.","oneSentence":"BCD-132 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:40.655Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Other solid tumors (under investigation)"}]},"trialDetails":[{"nctId":"NCT06987851","phase":"PHASE3","title":"An Extension Clinical Study of the Efficacy and Safety of BCD-132 in Patients With Multiple Sclerosis Who Previously Received Therapy in Clinical Studies of JSC BIOCAD","status":"COMPLETED","sponsor":"Biocad","startDate":"2022-03-22","conditions":"Multiple Sclerosis","enrollment":44},{"nctId":"NCT04056897","phase":"PHASE2","title":"Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple Sclerosis","status":"COMPLETED","sponsor":"Biocad","startDate":"2019-06-07","conditions":"Multiple Sclerosis","enrollment":271},{"nctId":"NCT05385744","phase":"PHASE3","title":"An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis","status":"COMPLETED","sponsor":"Biocad","startDate":"2021-04-05","conditions":"Multiple Sclerosis","enrollment":336},{"nctId":"NCT05730699","phase":"PHASE3","title":"Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biocad","startDate":"2022-12-12","conditions":"Neuromyelitis Optica Spectrum Disorders","enrollment":105},{"nctId":"NCT03551275","phase":"PHASE1","title":"Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Biocad","startDate":"2018-02-22","conditions":"Multiple Sclerosis","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["humanized monoclonal antibody against CD20"],"phase":"phase_3","status":"active","brandName":"BCD-132","genericName":"BCD-132","companyName":"Biocad","companyId":"biocad","modality":"Biologic","firstApprovalDate":"","aiSummary":"BCD-132 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses. Used for Non-small cell lung cancer, Other solid tumors (under investigation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}